PR Newswire - Antengene Announces XPOVIO® (selinexor) National H...
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma...
Read More

ภาษาไทย
English